PFM Health Sciences LP Acquires New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

PFM Health Sciences LP acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 233,410 shares of the biopharmaceutical company’s stock, valued at approximately $5,459,000.

Several other large investors also recently bought and sold shares of TGTX. Marshall Wace LLP purchased a new stake in TG Therapeutics during the 2nd quarter valued at about $36,501,000. Principal Financial Group Inc. grew its stake in shares of TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after buying an additional 725,371 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of TG Therapeutics in the 2nd quarter valued at approximately $10,423,000. Assenagon Asset Management S.A. purchased a new stake in shares of TG Therapeutics in the 2nd quarter valued at approximately $8,698,000. Finally, Public Sector Pension Investment Board purchased a new stake in shares of TG Therapeutics in the 3rd quarter valued at approximately $6,619,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now directly owns 100,195 shares in the company, valued at $3,049,935.80. This represents a 4.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.50% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on TGTX. HC Wainwright increased their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. increased their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. TD Cowen initiated coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They set a “buy” rating and a $50.00 price objective for the company. Finally, B. Riley increased their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $40.67.

TG Therapeutics Stock Performance

NASDAQ:TGTX opened at $34.80 on Friday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The stock has a market capitalization of $5.42 billion, a P/E ratio of -349.97 and a beta of 2.19. The company has a 50 day moving average price of $26.38 and a 200 day moving average price of $22.13. TG Therapeutics, Inc. has a fifty-two week low of $12.37 and a fifty-two week high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.73 earnings per share. Equities research analysts forecast that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.